American Society of Hirudotherapy

Deep vein thrombosis in arthroscopic surgery and chemoprophylaxis recommendation in an Asian population

Prospective cohort study published in Singapore medical journal (2016)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureYeo KS et al. · Singapore medical journal, 2016

Abstract

INTRODUCTION: There are currently no guidelines supporting the use of routine chemoprophylaxis to prevent deep vein thrombosis (DVT) in arthroscopic surgery. Studies and meta-analysis show opposing views on its routine use in arthroscopy. This study aimed to examine the incidence of DVT in a prospective cohort of knee arthroscopy and knee arthroplasty patients, and to analyse the risk factors contributing to DVT. METHODS: All patients scheduled to undergo knee arthroscopy or arthroplasty over a two-year period were included. A standardised regimen of postoperative mechanical prophylaxis and rehabilitation was applied to all patients. Only patients who were postoperatively symptomatic were referred for ultrasonography. DVT incidence was calculated, and univariate and multivariate analyses of the risk factors were performed. RESULTS: The overall incidence of DVT was 0.5% among the 1,410 arthroscopy patients and 3.1% among the 802 arthroplasty patients. The incidence of proximal DVT among the arthroscopy and arthroplasty patients was 0.4% and 1.1%, respectively. Multivariate analysis showed that age was the only significant predictor of DVT incidence. Using the receiver operating characteristic method, the cut-off age for the arthroscopy and arthroplasty patients was 52 years, while that for the arthroscopy patients only was 40 years (increased risk of DVT: 5.46 and 6.44 times, respectively; negative predictive value: 99.7% and 99.8%, respectively). CONCLUSION: DVT incidence among Asian arthroplasty and arthroscopy patients remains low, even without chemoprophylaxis. Since age was found to be a significant risk factor for DVT, DVT prophylaxis can be considered for patients in high-risk age groups.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultArthroplastyArthroplasty, Replacement, KneeAsian PeopleFemaleHumansIncidenceKnee JointMaleMiddle AgedMultivariate AnalysisProspective StudiesPulmonary EmbolismRehabilitationRisk FactorsSingaporeVenous Thrombosis

Summary

Prospective cohort of 1,410 arthroscopy and 802 arthroplasty patients found overall DVT incidence of 0.5% and 3.1% respectively; age was the only significant multivariate predictor, with cut-offs of 40 years (arthroscopy) and 52 years (combined).

Why This Matters for Hirudotherapy

This prospective cohort tracked symptomatic deep vein thrombosis after knee arthroscopy and arthroplasty in an Asian population, reporting low overall DVT incidence (0.5% arthroscopy, 3.1% arthroplasty) and identifying age as the only significant predictor, leading the authors to suggest selective rather than routine chemoprophylaxis. For hirudotherapy the connection is contextual rather than direct: it helps frame the background thrombosis-risk and anticoagulation landscape in which leech therapy and leech-derived anticoagulants are sometimes discussed, but the study involves no leeches or leech-derived agents. The honest caveat is that this is a single-population cohort about surgical DVT epidemiology and prophylaxis decisions; it offers no data on hirudotherapy and should not be presented as supporting it, only as part of the broader venous-thromboembolism evidence backdrop.

Citation

Reference (Vancouver style)

Yeo KS, Lim WS, Lee YH. Deep vein thrombosis in arthroscopic surgery and chemoprophylaxis recommendation in an Asian population. Singapore Med J. 2016;57(8):452-455. doi:10.11622/smedj.2016136. PMID: 27549352

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.